Cardiologists have taught us how to conduct large and rigorous clinical trials, but now cardiologists are using our endocrine tools! The beta-adrenergic signaling or the renin-angiotensin-aldosterone system, and more recently the SGLT2 inhibitors, are examples of how neuroendocrine control is central to cardiovascular function. In 'endocrine hands', we are taking back such tools to reveal the molecular players involved.
